Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(19):1480-1481; doi:10.1093/jnci/djh295
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Saad, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Saad, F.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer

Fred Saad

Correspondence to: Fred Saad, MD, FRCS, Department of Surgery/Urology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada H2L 4M1 (e-mail: fred.saad@ssss.gouv.qc.ca)

The first 10% of the full text of this article appears below.

Dr. Parker stated that in our trial (1) "zoledronic acid demonstrated statistically significant reductions in skeletal complications"; however, he questioned whether such reductions should be regarded as sufficient evidence to change clinical practice. First, he doubted the clinical significance of the statistically significant 0.47-point reduction we observed in the mean Brief Pain Inventory score . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
Christopher C. Parker
J Natl Cancer Inst 2004 96: 1480. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JCOHome page
R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta
Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
J. Clin. Oncol., November 10, 2005; 23(32): 8232 - 8241.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Miwa, A. Mizokami, E. T. Keller, R. Taichman, J. Zhang, and M. Namiki
The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4-Induced Invasion in Prostate Cancer
Cancer Res., October 1, 2005; 65(19): 8818 - 8825.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
K. J. Pienta and D. C. Smith
Advances in Prostate Cancer Chemotherapy: A New Era Begins
CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318.
[Abstract] [Full Text] [PDF]